- Home
- LPG vs SYRE Comparison
LPG vs SYRE Comparison
Compare LPG & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPG
- SYRE
- Stock Information
- Founded
- LPG 2013
- SYRE 2013
- Country
- LPG United States
- SYRE United States
- Employees
- LPG N/A
- SYRE N/A
- Industry
- LPG Marine Transportation
- SYRE Biotechnology: Pharmaceutical Preparations
- Sector
- LPG Consumer Discretionary
- SYRE Health Care
- Exchange
- LPG Nasdaq
- SYRE Nasdaq
- Market Cap
- LPG 913.3M
- SYRE 841.4M
- IPO Year
- LPG 2014
- SYRE 2016
- Fundamental
- Price
- LPG $25.76
- SYRE $15.52
- Analyst Decision
- LPG Strong Buy
- SYRE Buy
- Analyst Count
- LPG 1
- SYRE 6
- Target Price
- LPG $35.00
- SYRE $55.00
- AVG Volume (30 Days)
- LPG 644.6K
- SYRE 626.6K
- Earning Date
- LPG 07-31-2025
- SYRE 08-06-2025
- Dividend Yield
- LPG 12.47%
- SYRE N/A
- EPS Growth
- LPG N/A
- SYRE N/A
- EPS
- LPG 2.14
- SYRE N/A
- Revenue
- LPG $349,670,662.00
- SYRE N/A
- Revenue This Year
- LPG $12.19
- SYRE N/A
- Revenue Next Year
- LPG N/A
- SYRE N/A
- P/E Ratio
- LPG $12.00
- SYRE N/A
- Revenue Growth
- LPG N/A
- SYRE N/A
- 52 Week Low
- LPG $16.66
- SYRE $10.91
- 52 Week High
- LPG $43.85
- SYRE $40.26
- Technical
- Relative Strength Index (RSI)
- LPG 64.08
- SYRE 48.48
- Support Level
- LPG $24.16
- SYRE $14.00
- Resistance Level
- LPG $25.54
- SYRE $16.61
- Average True Range (ATR)
- LPG 0.75
- SYRE 1.30
- MACD
- LPG 0.01
- SYRE -0.12
- Stochastic Oscillator
- LPG 81.83
- SYRE 38.97
About LPG Dorian LPG Ltd.
Dorian LPG Ltd is an international liquefied petroleum gas shipping company focused on owning and operating gas carriers, or VLGCs. The company currently owns and operates around 22 modern VLGCs, including nineteen new fuel-efficient 84,000 cbm ECO-design VLGCs. Dorian LPG has offices in Connecticut, USA, London, United Kingdom, and Athens, Greece.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.